[ Price : $8.95]
Congress passes S 3905 Preventing Organizational Conflicts of Interest in Federal Acquisition Act that aims to curb government con...[ Price : $8.95]
Dr. Reddys subsidiary Aurigene Oncology halts the development of its psoriasis investigational drug after reporting poor results o...[ Price : $8.95]
FDA publishes a revised guidance incorporating GDUFA 3 performance goals for complete response letter activities.[ Price : $8.95]
FDA approves revised labeling for Genentechs Xeloda.[ Price : $8.95]
FDA extends by three months its review of an AstraZeneca and Merck supplemental NDA for Lynparza (olaparib) in combination with Ja...[ Price : $8.95]
OMB approves seven information collections that include humanitarian-use devices, Right-to-Try Act reporting, and positron emissio...[ Price : $8.95]
Three drug companies comment on an FDA draft guidance on immune-mediated adverse reactions in cancer drug trials.[ Price : $8.95]
Federal Register notice: FDA sends to OMB an information collection extension entitled Conflict-of-Interest Information for Partic...